The effect of calciteriol supplementation on metabolic indices and blood pressure, in patients with type 2 diabetes: A double blind randomized clinical trial

According to previous studies, vitamin D has an inverse relation with some of the lipid and glucose profiles, and its deficiency is a risk factor for type 2 diabetes and cardiovascular disease. Therefore, the aim of this study was to evaluate the effect of vitamin D (calcitriol) on the blood glucose, lipid and hypertension profile in type 2 diabetic patients.
In this Double blinded randomized clinical trial, 90 patients with type 2 diabetes and serum 25-Hydroxy vitamin D levels of less than 30 ng/ml recruited from “Besat Diabetes Clinic” in Rasht, Guilan, North of Iran. The subjects took 50000 IU vitamin D supplements or placebo for 8 weeks. The primary outcomes of this study were 25 hydroxyvitamin D levels, serum hemoglobin glycosylated and HDL cholesterol, and secondary outcomes of this study, fasting blood glucose and insulin, resistance and insulin sensitivity, other components of lipid and blood pressure, which were studied before and after intervention and between the two groups were compared.
Vitamin D supplementation significantly increased serum calcitriol and HDL cholesterol levels, as well as a significant decrease of 1% in serum hemoglobin glycosylated (p0.05).
Based on the findings of this study, weekly supplementation with 50,000 units of vitamin D for 8 weeks, while compensating for the deficiency of serum levels of this vitamin, reduced glycosylated hemoglobin and increased HDL cholesterol in type 2 diabetic patients, but had no effect on serum fasting glucose and insulin, insulin resistance and sensitivity and hypertension in these patients.